Biomarkers for Predicting Response to Immune Checkpoint Blockers

Abstract

Cancer remains a leading cause of mortality among Americans and the lung is the primary site of origin for these deaths. Among available treatments for metastatic lung cancer, immune checkpoint blockers are associated with the best survival rates, with anti-PD1/PDL1 monoclonal antibodies (mAb). Yet, even this therapeutic advance benefits only a minority (<20 percent) of metastatic lung cancer patients. Furthermore, there are no good markers for sorting which patients will or will not respond to treatment. Our purpose is to identify biomarkers that reliably prognosticate responsiveness (vs. resistance) of metastatic lung cancer patients to antiPD1/PDL1 mAb.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1152699

Entities

People

  • Kiyoshi Ariizumi

Organizations

  • University of Texas at Dallas

Tags

DTIC Thesaurus Topics

  • Blood
  • Cancer
  • Cardiovascular System
  • Cells
  • Chemistry
  • Data Science
  • Electronic Mail
  • Gene Expression
  • Health Services
  • Hematopoietic Cells
  • Institutional Review Board
  • Leukocytes
  • Lymphatic System
  • Lymphocytes
  • Medical Personnel
  • Oncology
  • Proteins
  • Resistance
  • Statistical Analysis
  • Therapy

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Oncology